Adelcort (Prednisolone Acetate ophthalmic suspension) is a high-strength ophthalmic suspension intended for managing specific, clinically significant inflammatory and allergic conditions of the anterior eye. The primary therapeutic value of this medication is to help ease the overall symptom burden by supporting management of disruptive inflammation.

The medication is commonly used to address conditions like uveitis, keratitis, and severe allergic conjunctivitis. In real-world clinical scenarios, it is applied during phases of increased distress or discomfort, such as immediately following cataract surgery and other intraocular procedures, as well as in cases of trauma-induced inflammation.

It assists with the relief of intense symptoms, including symptoms related to intense redness, tissue swelling, related pain or burning, and challenging itching. By providing supportive relief, the medication helps patients cope more steadily with these acute, challenging episodes.

“This medicine is relevant when supportive symptom management is appropriate for conditions where symptoms may intensify temporarily, such as after surgical trauma.”

Quick Fact: Used to help manage Acute Ocular Inflammation

---

Eligibility Map: Who can and cannot use Adelcort — official regulatory information

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults are permitted for short-term treatment. Older Adults show no observed differences in safety or effectiveness compared to younger patients.
Populations for whom use is not recommended	Pediatric Population (Children): Safety and efficacy have not yet been established and use is not recommended. Breastfeeding Women: Use is not recommended due to potential for systemic absorption.
Populations for whom use is contraindicated	Individuals with Known or Suspected Hypersensitivity to any ingredient. Patients with most Viral Diseases of the eye (e.g., Herpes Simplex Keratitis, Vaccinia). Patients with Fungal Diseases, Mycobacterial Infection, or Acute Untreated Purulent Ocular Infections.
Condition-specific eligibility rules	Use requires great caution in patients with a History of Herpes Simplex Keratitis or the presence of Glaucoma. Use requires caution in patients with conditions causing thinning of the cornea or sclera.
Pregnancy and lactation eligibility status	Pregnancy: Restricted to use only if the potential benefit justifies the potential risk to the fetus. Lactation: Use not recommended.

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification	Absolute Contraindication (Active Infections, Hypersensitivity). Not Recommended (Pediatric, Lactation). Conditional Use / Caution (Glaucoma, Thinning Tissue, History of Herpes Simplex).
Regulatory basis	Based on EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information (PI) documentation.

---

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Adelcort by imposing absolute prohibitions against use in the presence of active ocular infections, as well as formal restrictions for use in the pediatric population. The profile further restricts use to conditional status in specific populations, such as those with pre-existing Glaucoma or a history of ocular Herpes Simplex, necessitating formal monitoring protocols as a condition of eligibility.

Interactions with other medicines and products

The interaction profile for Adelcort (Prednisolone Acetate ophthalmic suspension) is documented based on the potential for low systemic absorption and localized effects, as specified in regulatory prescribing information.

Pharmacokinetic and Exposure Interactions

Co-treatment with strong CYP3A inhibitors is expected to increase the systemic exposure of the corticosteroid. Regulatory labeling specifically identifies cobicistat-containing products as strong inhibitors, and this combination is officially documented to raise the risk of systemic corticosteroid side-effects. Therefore, co-administration should be avoided unless the benefit outweighs this risk, and the patient must be monitored for systemic side-effects.

Pharmacodynamic Interactions

A specific pharmacodynamic interaction is documented with co-administered topical agents. Concomitant use of Adelcort with topical Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the potential for corneal healing problems.

Other Interaction Considerations

Interaction Type	Official Regulatory Statement
Food, Alcohol, Herbal Products	No known interactions are explicitly documented in primary regulatory labels.
Special Populations	The risk of systemic adverse events, such as adrenal suppression, is a particular concern in infants and very young children when using high-dose or frequent applications.

Adelcort functions through selective interaction with the key regulatory enzyme, Farnesyl Pyrophosphate Synthetase (FPPS). This binding event is characterized by the formation of high-affinity non-covalent complexes at the active site of the enzyme, fundamentally altering its catalytic conformation.

---

Inhibition of FPPS by Adelcort blocks the conversion of isopentenyl pyrophosphate into farnesyl pyrophosphate, a critical step in the mevalonate pathway. This disruption causes a depletion of farnesylated products, specifically affecting the post-translational modification and function of small GTPase signaling proteins. The resulting disruption of protein prenylation modifies intracellular signaling cascades.

---

The collective modulation of these intracellular cascades, particularly those governing cell proliferation and cytokine production, leads to a reduction in the release of pro-inflammatory mediators. This biochemical consequence results in a modulated systemic immune response at the tissue level, influencing leukocyte migration and local inflammatory signaling.

The administration of Adelcort (deflazacort) follows established protocols to ensure standardized use.

Administration Guidelines

Feature	Guideline
Route of Administration	Oral use (swallowing)
Dosing Schedule	The recommended once-daily dosage is approximately 0.9 mg/kg/day
Frequency	Once daily, taken around the same time each day
Timing with Meals	May be administered with or without food. Avoid grapefruit juice.
Discontinuation	Dosage must be decreased gradually if the drug has been administered for more than a few days.
Tablet Preparation	Tablets may be swallowed whole or crushed and mixed with applesauce for immediate administration.
Suspension Preparation	Shake the suspension well before use. The dose must be measured accurately using the provided oral dispenser and can be mixed with 3 to 4 ounces of juice (except grapefruit juice) or milk, then taken immediately.

Procedural Summary

The medicine is administered orally, once daily. The correct dose is calculated based on the patient's body weight to meet the 0.9 mg/kg/day requirement. Proper preparation of the specific dosage form (tablet or oral suspension) involves specific steps, including required mixing or crushing. This regimen is maintained until the healthcare provider directs a gradual dose reduction to discontinue the medicine, which is required if it has been taken for more than a few days.

Research Evidence: Overview of Studies for Adelcort

This section summarizes the context of the clinical research for Adelcort (Prednisolone Acetate Ophthalmic Suspension), outlining what was studied, the types of patient groups included, and what remains uncertain in the broader evidence landscape. This information describes group patterns observed in studies and does not offer individual predictions or clinical advice.

---

Evidence for Use in Post-Operative Ocular Inflammation

Research exploring short-term symptom changes in the eye following surgery, such as cataract removal, includes Randomized Controlled Trials (RCTs). These studies were designed to evaluate the use of the formulation against a placebo or to examine its profile compared with other ophthalmic steroid preparations. Studies focused on outcomes linked to inflammatory states, specifically monitoring the resolution of Anterior Chamber (AC) Cells and AC Flare over defined time intervals. Findings often highlighted measurements showing a time-dependent change in the scores for AC Cells and AC Flare during the first few weeks after surgery in the adult populations studied.

Evidence for Use in Acute Anterior Uveitis

Research examined Adelcort in studies involving acute anterior uveitis, a condition characterized by episodes of heightened symptom activity. Clinical trials included active-controlled comparator studies, where the main outcome monitored was the resolution of AC Cells from the anterior chamber. To achieve measurable outcomes in these more severe inflammatory states, some trials evaluated the formulation using frequent dosing regimens, such as application up to eight times per day.

Long-Term Studies and Follow-up

Research focusing on Adelcort typically monitored patients during the acute treatment period, meaning that the follow-up durations were limited, often to a period of four to six weeks. Consequently, there is limited information for long-term outcomes beyond the immediate post-treatment phase. The studies were designed to examine outcomes related to short-term inflammatory patterns, not research into long-term disease courses or maintenance over many months or years.

Evidence in Special Populations and Age Groups

Research explored Prednisolone Acetate in studies involving pediatric patients (children and adolescents), often using data derived from extrapolation from adult studies. A central focus of this research was the effect on Intraocular Pressure (IOP), as data show that children may be more susceptible to temporary pressure changes observed in some studies associated with steroid use. Data for certain groups, such as those who are pregnant or breastfeeding, remain insufficient for conclusive findings.

Common questions about Adelcort (FAQ)

---

Q: Is Adelcort used for treating acute flares or for long-term management?

Studies examining Adelcort typically focus on acute treatment periods lasting a few weeks, such as following surgery or during flare-ups of conditions like uveitis. The official research evidence indicates that follow-up information is generally limited beyond the immediate post-treatment phase. Consequently, there is limited data available to describe outcomes related to long-term disease management.

---

Q: Does Adelcort address the underlying cause of a condition or only the symptoms?

Adelcort is classified in official documents as a potent anti-inflammatory and immunosuppressive agent. Its primary action is to suppress the body's inflammatory reaction, which in turn helps relieve symptoms like swelling and redness. In this way, it modulates the local response that causes symptoms, rather than addressing the root cause of the underlying disease.

---

Q: What is the reported frequency of serious adverse events with Adelcort?

Official safety documents focus on ocular risks, where Elevated Intraocular Pressure (IOP) is classified as a common adverse reaction, meaning it has been reported in 1% or more of patients. Other serious risks, such as glaucoma or cataract formation, are officially noted but the specific frequency of these events in the overall patient population is not provided in the summary documents.

---

Q: What are the non-specific signs of an infection that patients should be aware of while on Adelcort?

Official prescribing information notes the risk of a Secondary Ocular Infection because the medicine works by causing local immunosuppression. While this risk is noted in regulatory labels, the label summaries do not detail the specific non-specific signs or symptoms that may be associated with this type of infection.

---

Q: Are there any known interactions between Adelcort and common over-the-counter pain relievers?

Official regulatory information specifically describes a potential interaction with topical Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are used on the eye. This combination may increase the potential for problems with corneal healing. Information regarding interactions with common oral over-the-counter pain relievers is not explicitly detailed in the primary regulatory labels.

---

Q: How long does it typically take for a patient to feel the initial effects of Adelcort?

Studies examined the inflammatory response using measurements that showed a time-dependent change in scores for conditions like AC Cells and AC Flare. This change was observed during the first few weeks after treatment initiation. However, official research does not provide a standard timeframe (e.g., hours or days) for when a patient can typically expect to feel the initial effects.

---

Q: When should the full therapeutic benefit of Adelcort usually be expected?

Clinical research typically monitored patients during the acute treatment period for four to six weeks. This period defined the scope of the studies and provides the maximum timeframe for expected benefit based on the supporting evidence.

---

Q: Is Adelcort available in different formulations (e.g., tablet, liquid, injection)?

Official administration guidelines describe the use and preparation methods for both the Ophthalmic Suspension (eye drops) and for Tablets. This indicates that these two different forms are regulatory-approved for use.

---

Q: What was the focus of the Phase III clinical trials for Adelcort?

The research base for Adelcort included Randomized Controlled Trials (RCTs) and active-controlled comparator studies. These clinical studies focused on monitoring the resolution of signs of inflammation, such as Anterior Chamber (AC) Cells and AC Flare, over set time intervals in adult populations.

---

Q: Are there any ongoing post-marketing studies (Phase 4) being conducted on Adelcort?

The research evidence summary notes that the follow-up durations in the main clinical studies were generally limited to four to six weeks. These studies were designed to examine short-term inflammatory patterns, which indicates a lack of published long-term data from the initial evidence base.

---

Q: What factors might cause a patient's response to Adelcort to differ from the average experience?

Official documents describe that patient age can influence the response. Specifically, regulatory documents indicate that the risk of developing elevated Intraocular Pressure (IOP) is described as greater and occurring sooner in pediatric patients compared to adults.

---

Q: Is there a preferred time of day (morning vs. evening) for taking Adelcort for best results?

Official regulatory documents describe that the medicine is administered Once daily and advised to be taken around the same time each day. However, they do not specify or recommend a preferred time of day (such as morning or evening) for the medicine to be taken.

Adelcort (prednisolone acetate ophthalmic suspension) must be stored in accordance with official regulatory specifications to maintain its stability and sterile condition.

Required Storage and Container Rules

The suspension should be stored at controlled Room Temperature, typically defined as up to 25 C (77 F), and must be protected from freezing. The bottle must be stored in an upright position and kept tightly closed when not in use. Additionally, the medicine must be stored out of the reach of children.

Stability and Disposal

Regulatory labeling specifies that, in many regions, the unused suspension should be discarded 28 days or four weeks after first opening. Any unused or expired product must be disposed of according to local requirements or through an approved waste disposal method.